Stock analysts at Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) in a ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Leerink notes that shares of Outperform-rated Sarepta (SRPT) are under pressure on the heels of the disclosure of a patient death following ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Shattuck Labs (NasdaqGS:STTK) with a Outperform ...

Leerink analyst Andrew Berens notes that Outperform-rated Incyte (INCY) has reported the results of the two parallel Phase 3 trials evaluating ...

Fintel reports that on March 17, 2025, Leerink Partners initiated coverage of Nurix Therapeutics (NasdaqGM:NRIX) with a ...

Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

A webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days. About AdageneAdagene Inc. (Nasdaq: ADAG) is ...